Conformis, Inc. (CFMS)

Market Cap	26.54M
Revenue (ttm)	60.05M
Net Income (ttm)	-62.73M
Shares Out	7.25M
EPS (ttm)	-0.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	Nov 10, 2022

Volume	204,944
Open	3.54
Previous Close	3.52
Day's Range	3.53 - 4.22
52-Week Range	1.2 - 21.3
Beta	1.09
Analysts	Buy
Price Target	23.97 (+544.4%)
Earnings Date	Nov 2, 2022

About CFMS

Conformis, Inc., a medical technology company, develops, manufactures, and sells patient-specific products and instrumentation. The company offers personalized knee replacement products, including iUni, iDuo, a custom-made partial knee replacement option for either unicompartmental or bicompartmental osteoarthritis of the knee; iTotal CR, a cruciate retaining total knee replacement product; iTotal PS, a posterior stabilized knee replacement product, as well as provides iTotal Identity and Identity Imprint knee replacement products. It also prov...

• Industry: Health Care Equipment & Supplies
• IPO Date: Jul 1, 2015
• Employees: 310
• Stock Exchange: NASDAQ
• Ticker Symbol: CFMS

Financial Performance

In 2021, Conformis's revenue was $99.86 million, an increase of 45.23% compared to the previous year's $68.76 million. Losses were -$2.41 million, -90.07% less than in 2020.

Analyst Forecast

According to 9 analysts, the average rating for CFMS stock is "Buy." The 12-month stock price forecast is 23.97, which is an increase of 544.35% from the latest price.

Price Target

$23.97

(544.35% upside)

Analyst Consensus: Buy